Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
28261 | 211 | 24.9 | 47% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
315 | 3 | ALLERGY//MAST CELLS//BRADYKININ | 39886 |
1331 | 2 | ALLERGIC RHINITIS//ANTIHISTAMINES//ALLERGIC CONJUNCTIVITIS | 8385 |
28261 | 1 | NAFAMOSTAT MESILATE//SODIUM BISULFITE SBS//COLLECTING DUCT CELL | 211 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | NAFAMOSTAT MESILATE | authKW | 1779675 | 16% | 36% | 34 |
2 | SODIUM BISULFITE SBS | authKW | 289435 | 1% | 100% | 2 |
3 | COLLECTING DUCT CELL | authKW | 217073 | 1% | 50% | 3 |
4 | 6 AMIDINO 2 NAPHTHOL | authKW | 192955 | 1% | 67% | 2 |
5 | P GUANIDINOBENZOIC ACID | authKW | 192955 | 1% | 67% | 2 |
6 | SYNTHETIC PROTEASE INHIBITOR | authKW | 186062 | 1% | 43% | 3 |
7 | NAFAMOSTAT | authKW | 172275 | 2% | 24% | 5 |
8 | 1 N N BISBENZYLOXYCARBONYLAMIDINOPYRAZOLE | authKW | 144718 | 0% | 100% | 1 |
9 | 20 KDA FIBRINOLYTIC FRAGMENT | authKW | 144718 | 0% | 100% | 1 |
10 | 9 4 ACETYL 3 HYDROXY 2 N PROPYL PHENOXYMETHYL 3 1H TETRAZOL 5 YL 4H PYRIDO 1 2 APYRIMIDIN 4 ONE PHARMACOLOGY | authKW | 144718 | 0% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 1052 | 42% | 0% | 88 |
2 | Chemistry, Medicinal | 702 | 18% | 0% | 37 |
3 | Transplantation | 224 | 7% | 0% | 15 |
4 | Hematology | 216 | 10% | 0% | 22 |
5 | Peripheral Vascular Diseases | 117 | 8% | 0% | 16 |
6 | Engineering, Biomedical | 107 | 6% | 0% | 13 |
7 | Chemistry, Multidisciplinary | 73 | 15% | 0% | 31 |
8 | Surgery | 25 | 8% | 0% | 17 |
9 | Respiratory System | 15 | 3% | 0% | 6 |
10 | Allergy | 14 | 1% | 0% | 3 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CHUNCHEON SACRED HEART HOSP ANESTHESIOL | 144718 | 0% | 100% | 1 |
2 | CHUNCHEON SACRED HEART HOSP INTERNAL MED | 144718 | 0% | 100% | 1 |
3 | CHUNCHEON SACRED HEART HOSP UROL | 144718 | 0% | 100% | 1 |
4 | QUEEN SILVIAS CHILDRENS HOSP SU OSTRA HLTH W | 144718 | 0% | 100% | 1 |
5 | SURG DNA MED | 144718 | 0% | 100% | 1 |
6 | MINATO KU MED | 72358 | 0% | 50% | 1 |
7 | POLICY INFORMAT | 56468 | 2% | 10% | 4 |
8 | HOSP PHARM TSUKINOWA CHO | 48238 | 0% | 33% | 1 |
9 | MOL CELL ONCOL | 48238 | 0% | 33% | 1 |
10 | BIOMED DENT MAT | 36178 | 0% | 25% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | FOLIA PHARMACOLOGICA JAPONICA | 10658 | 4% | 1% | 9 |
2 | CHEMICAL & PHARMACEUTICAL BULLETIN | 4056 | 10% | 0% | 22 |
3 | JAPANESE JOURNAL OF PHARMACOLOGY | 3295 | 5% | 0% | 10 |
4 | YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN | 2770 | 5% | 0% | 10 |
5 | ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH | 2658 | 4% | 0% | 9 |
6 | HAEMOSTASIS | 1867 | 2% | 0% | 4 |
7 | THROMBOSIS RESEARCH | 1403 | 5% | 0% | 10 |
8 | ARTIFICIAL ORGANS | 813 | 2% | 0% | 5 |
9 | JOURNAL OF PHARMACOBIO-DYNAMICS | 795 | 1% | 0% | 3 |
10 | JOURNAL OF PHARMACOLOGICAL SCIENCES | 555 | 1% | 0% | 3 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | FUJIWARA, Y , SHIBA, H , UWAGAWA, T , FUTAGAWA, Y , MISAWA, T , YANAGA, K , (2015) RADICAL RESECTION OF A PRIMARILY UNRESECTABLE PANCREATIC CANCER AFTER NEOADJUVANT CHEMOTHERAPY USING GEMCITABINE, TS-1, AND NAFAMOSTAT MESILATE; REPORT OF A CASE.INTERNATIONAL SURGERY. VOL. 100. ISSUE 2. P. 287 -291 | 10 | 59% | 0 |
2 | MIYATA, M , SHIRAKAWA, T , ACHARYA, B , TERAO, S , GOTOH, A , (2006) EFFECTS OF NAFAMOSTAT MESILATE ON ADP-INDUCED PLATELET AGGREGATION AND DISAGGREGATION IN HEMODIALYSIS PATIENTS.ASAIO JOURNAL. VOL. 52. ISSUE 3. P. 272-275 | 12 | 60% | 3 |
3 | NISHIMURA, H , YAMAYA, M , (2015) A SYNTHETIC SERINE PROTEASE INHIBITOR, NAFAMOSTAT MESILATE, IS A DRUG POTENTIALLY APPLICABLE TO THE TREATMENT OF EBOLA VIRUS DISEASE.TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE. VOL. 237. ISSUE 1. P. 45 -50 | 9 | 53% | 1 |
4 | LIM, JY , KIM, JB , CHOO, SJ , CHUNG, CH , LEE, JW , JUNG, SH , (2016) ANTICOAGULATION DURING EXTRACORPOREAL MEMBRANE OXYGENATION; NAFAMOSTAT MESILATE VERSUS HEPARIN.ANNALS OF THORACIC SURGERY. VOL. 102. ISSUE 2. P. 534 -539 | 9 | 47% | 0 |
5 | TANIZAWA, K , (1985) DEVELOPMENT OF INVERSE SUBSTRATES FOR TRYPSIN - APPLICATION TO THE STUDIES ON THE STRUCTURE AND FUNCTION OF ENZYME AND TO THE DESIGN FOR BIOLOGICALLY-ACTIVE COMPOUNDS.YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN. VOL. 105. ISSUE 5. P. 430 -441 | 14 | 93% | 0 |
6 | TAKASU, Y , YOSHIDA, M , TANGE, M , ASAHARA, K , UCHIDA, T , (2015) PREDICTION OF THE STABILITY OF MEROPENEM IN INTRAVENOUS MIXTURES.CHEMICAL & PHARMACEUTICAL BULLETIN. VOL. 63. ISSUE 4. P. 248 -254 | 5 | 83% | 0 |
7 | IWASE, R , HARUKI, K , FUJIWARA, Y , FURUKAWA, K , SHIBA, H , UWAGAWA, T , MISAWA, T , OHASHI, T , YANAGA, K , (2013) COMBINATION CHEMOTHERAPY OF NAFAMOSTAT MESYLATE WITH GEMCITABINE FOR GALLBLADDER CANCER TARGETING NUCLEAR FACTOR-KAPPA B ACTIVATION.JOURNAL OF SURGICAL RESEARCH. VOL. 184. ISSUE 1. P. 605 -612 | 12 | 35% | 3 |
8 | KONO, K , TATARA, I , TAKEDA, S , ARAKAWA, K , (1996) NAFAMOSTAT MESYLATE THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHROTIC SYNDROME: A CASE REPORT.CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL. VOL. 57. ISSUE 6. P. 438-444 | 8 | 80% | 0 |
9 | TANIZAWA, K , KANAOKA, Y , LAWSON, WB , (1987) INVERSE SUBSTRATES FOR TRYPSIN AND TRYPSIN-LIKE ENZYMES.ACCOUNTS OF CHEMICAL RESEARCH. VOL. 20. ISSUE 9. P. 337-343 | 12 | 75% | 15 |
10 | TAKASU, Y , YOSHIDA, M , SHIMIZU, K , ASAHARA, K , TANGE, M , UCHIDA, T , (2014) PREDICTION OF THE STABILITY OF OCTREOTIDE IN A MIXED INFUSION.CHEMICAL & PHARMACEUTICAL BULLETIN. VOL. 62. ISSUE 4. P. 316-321 | 5 | 71% | 0 |
Classes with closest relation at Level 1 |